TMED6

Across TCGA pan-cancer cohorts, TMED6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMED6 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMED6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMED6 expression acts as an unfavorable survival marker.

HNSC, ESCA, and PRAD are the cancer types where TMED6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.118	0.756	<.001	18	view →
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	IV	0.140	0.483	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.424	0.787	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMED6–HNSC (OS)

Open the HNSC breakdown →